Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996265 · ClinicalTrials.gov registry record · Phase 3
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
A Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by University of Rochester NCORP Research Base.
- Active
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
- 20
- Study locations
NCT03996265: Active Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, sponsored by University of Rochester NCORP Research Base.
NCT03996265 is a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm that is active but no longer recruiting, run by University of Rochester NCORP Research Base. The registered enrollment target is 422 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03996265, a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphatic System Neoplasm, is active but no longer recruiting, sponsored by University of Rochester NCORP Research Base.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Primary Outcome
Measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue subscale (FFS). Scale scores range from 0-4; lower scores indicate greater fatigue. Will use analysis of covariance with group as the main factor and baseline FFS as a covariate.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Bupropion Hydrochloride Controlled-release
- OTHER Placebo Administration
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- PCR Oncology - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- Contra Costa Regional Medical Center - Martinez
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Arizona
- Kingman Regional Medical Center - Kingman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2026-08-05 |
| Phase | Phase 3 |
What the registry record for NCT03996265 still lists
NCT03996265 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03996265 names 20 study sites across 4 states, led by Alaska, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03996265 about?
NCT03996265 is a clinical study titled "Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors". This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepress...
What is the current status of trial NCT03996265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2019-06-27. Estimated completion is 2026-08-05.
What conditions does trial NCT03996265 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm.
What interventions are being tested in trial NCT03996265?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Bupropion Hydrochloride Controlled-release (DRUG), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT03996265?
This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03996265 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03996265's enrollment target sits among peer trials
422 34th of 176 higher than 143 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · Phase 3
-
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
RECRUITING · Phase 3
-
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RECRUITING · Phase 3
-
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI